CN101611317B - 肝脏炎症的生物标志物 - Google Patents
肝脏炎症的生物标志物 Download PDFInfo
- Publication number
- CN101611317B CN101611317B CN200780029721.3A CN200780029721A CN101611317B CN 101611317 B CN101611317 B CN 101611317B CN 200780029721 A CN200780029721 A CN 200780029721A CN 101611317 B CN101611317 B CN 101611317B
- Authority
- CN
- China
- Prior art keywords
- glu
- lys
- ala
- leu
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004185 liver Anatomy 0.000 title abstract description 20
- 206010061218 Inflammation Diseases 0.000 title abstract description 6
- 230000004054 inflammatory process Effects 0.000 title abstract description 6
- 239000000090 biomarker Substances 0.000 title description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 102000005937 Tropomyosin Human genes 0.000 claims abstract description 31
- 108010030743 Tropomyosin Proteins 0.000 claims abstract description 31
- 239000000523 sample Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 18
- 102000003932 Transgelin Human genes 0.000 claims abstract description 12
- 108090000333 Transgelin Proteins 0.000 claims abstract description 12
- 102100025413 Formyltetrahydrofolate synthetase Human genes 0.000 claims abstract description 7
- 101710096076 Malate dehydrogenase, mitochondrial Proteins 0.000 claims abstract description 7
- 102100039742 Malate dehydrogenase, mitochondrial Human genes 0.000 claims abstract description 7
- 108010010685 Methenyltetrahydrofolate cyclohydrolase Proteins 0.000 claims abstract description 7
- 108010065472 Vimentin Proteins 0.000 claims abstract description 7
- 210000005048 vimentin Anatomy 0.000 claims abstract description 7
- 101710170648 Actin, alpha cardiac muscle 1 Proteins 0.000 claims abstract description 6
- 239000012472 biological sample Substances 0.000 claims abstract description 6
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 claims abstract description 5
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 claims abstract description 5
- 102000053640 Argininosuccinate synthases Human genes 0.000 claims abstract description 5
- 108700024106 Argininosuccinate synthases Proteins 0.000 claims abstract description 5
- 101710137044 Fibrinogen alpha chain Proteins 0.000 claims abstract description 5
- 102100031829 Myosin light polypeptide 6 Human genes 0.000 claims abstract description 5
- 101710101143 Myosin light polypeptide 6 Proteins 0.000 claims abstract description 5
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims abstract description 5
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims abstract description 5
- 108010045517 Serum Amyloid P-Component Proteins 0.000 claims abstract description 5
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 5
- 102100031752 Fibrinogen alpha chain Human genes 0.000 claims abstract 2
- 102000013127 Vimentin Human genes 0.000 claims abstract 2
- 208000031816 Pathologic Dilatation Diseases 0.000 claims description 15
- 239000000975 dye Substances 0.000 claims description 15
- 208000011580 syndromic disease Diseases 0.000 claims description 15
- 238000001502 gel electrophoresis Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 210000003470 mitochondria Anatomy 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 102100028704 Acetyl-CoA acetyltransferase, cytosolic Human genes 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 101000837584 Homo sapiens Acetyl-CoA acetyltransferase, cytosolic Proteins 0.000 claims description 5
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 238000001155 isoelectric focusing Methods 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 101150049307 EEF1A2 gene Proteins 0.000 claims description 4
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 claims description 4
- 102100024944 Tropomyosin alpha-4 chain Human genes 0.000 claims description 4
- 101710193115 Tropomyosin alpha-4 chain Proteins 0.000 claims description 4
- 238000004638 bioanalytical method Methods 0.000 claims description 4
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 2
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000012317 liver biopsy Methods 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims 2
- 102100027573 ATP synthase subunit alpha, mitochondrial Human genes 0.000 claims 1
- 101000936262 Homo sapiens ATP synthase subunit alpha, mitochondrial Proteins 0.000 claims 1
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 35
- 230000007882 cirrhosis Effects 0.000 abstract description 32
- 102000007469 Actins Human genes 0.000 abstract description 5
- 108010085238 Actins Proteins 0.000 abstract description 5
- 102100027211 Albumin Human genes 0.000 abstract description 4
- 101100001390 Homo sapiens ALB gene Proteins 0.000 abstract description 4
- -1 hMFAP 4 Proteins 0.000 abstract description 4
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 abstract description 3
- 102100033076 Prostaglandin E synthase Human genes 0.000 abstract description 3
- 108010006229 Acetyl-CoA C-acetyltransferase Proteins 0.000 abstract description 2
- 101000911596 Homo sapiens Myelin-associated neurite-outgrowth inhibitor Proteins 0.000 abstract description 2
- 101000679406 Homo sapiens Tubulin polymerization-promoting protein family member 3 Proteins 0.000 abstract description 2
- 108050007056 Regucalcin Proteins 0.000 abstract description 2
- 102100037768 Acetyl-CoA acetyltransferase, mitochondrial Human genes 0.000 abstract 1
- 102100033620 Calponin-1 Human genes 0.000 abstract 1
- 101710092112 Calponin-1 Proteins 0.000 abstract 1
- 102100022272 Fructose-bisphosphate aldolase B Human genes 0.000 abstract 1
- 101710123710 Fructose-bisphosphate aldolase B Proteins 0.000 abstract 1
- 102000008934 Muscle Proteins Human genes 0.000 abstract 1
- 108010074084 Muscle Proteins Proteins 0.000 abstract 1
- 102000017955 Regucalcin Human genes 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000011847 diagnostic investigation Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 38
- 206010016654 Fibrosis Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 19
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 18
- 108010044940 alanylglutamine Proteins 0.000 description 16
- 210000005229 liver cell Anatomy 0.000 description 16
- 208000006454 hepatitis Diseases 0.000 description 15
- 108010005233 alanylglutamic acid Proteins 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 208000018191 liver inflammation Diseases 0.000 description 11
- 208000005176 Hepatitis C Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 8
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 8
- QPRZKNOOOBWXSU-CIUDSAMLSA-N Glu-Asp-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N QPRZKNOOOBWXSU-CIUDSAMLSA-N 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 108010049041 glutamylalanine Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 6
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 6
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 6
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 5
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 5
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 5
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 5
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 5
- XYLSGAWRCZECIQ-JYJNAYRXSA-N Lys-Tyr-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 XYLSGAWRCZECIQ-JYJNAYRXSA-N 0.000 description 5
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 5
- PVDTYLHUWAEYGY-CIUDSAMLSA-N Ser-Glu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PVDTYLHUWAEYGY-CIUDSAMLSA-N 0.000 description 5
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 5
- 102100035071 Vimentin Human genes 0.000 description 5
- 210000003995 blood forming stem cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 5
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 4
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 4
- OQWQTGBOFPJOIF-DLOVCJGASA-N Ala-Lys-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N OQWQTGBOFPJOIF-DLOVCJGASA-N 0.000 description 4
- YQGZIRIYGHNSQO-ZPFDUUQYSA-N Arg-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YQGZIRIYGHNSQO-ZPFDUUQYSA-N 0.000 description 4
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 4
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 4
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 4
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 4
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 4
- BLOXULLYFRGYKZ-GUBZILKMSA-N Gln-Glu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BLOXULLYFRGYKZ-GUBZILKMSA-N 0.000 description 4
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 4
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 4
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 4
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 4
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 4
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 4
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 4
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 4
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 4
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 4
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 4
- WKUXWMWQTOYTFI-SRVKXCTJSA-N Lys-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N WKUXWMWQTOYTFI-SRVKXCTJSA-N 0.000 description 4
- UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 4
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 4
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 4
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 4
- WVRUKYLYMFGKAN-IHRRRGAJSA-N Tyr-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WVRUKYLYMFGKAN-IHRRRGAJSA-N 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 108010041407 alanylaspartic acid Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 108010092854 aspartyllysine Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 4
- 108010025488 pinealon Proteins 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 3
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 3
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 3
- WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 3
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 3
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 3
- 102100025580 Calmodulin-1 Human genes 0.000 description 3
- 101710164735 Calmodulin-1 Proteins 0.000 description 3
- 102400000524 Fibrinogen alpha chain Human genes 0.000 description 3
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 description 3
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 3
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 3
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 3
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 3
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 3
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 3
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 3
- UDBPXJNOEWDBDF-XUXIUFHCSA-N Ile-Lys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)N UDBPXJNOEWDBDF-XUXIUFHCSA-N 0.000 description 3
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 3
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 3
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 3
- CHQWUYSNAOABIP-ZPFDUUQYSA-N Met-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)N CHQWUYSNAOABIP-ZPFDUUQYSA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 3
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 3
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 3
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 3
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 3
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 2
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- ZCUFMRIQCPNOHZ-NRPADANISA-N Ala-Val-Gln Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZCUFMRIQCPNOHZ-NRPADANISA-N 0.000 description 2
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 2
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 2
- XSGBIBGAMKTHMY-WHFBIAKZSA-N Asn-Asp-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O XSGBIBGAMKTHMY-WHFBIAKZSA-N 0.000 description 2
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 2
- BGINHSZTXRJIPP-FXQIFTODSA-N Asn-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BGINHSZTXRJIPP-FXQIFTODSA-N 0.000 description 2
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 2
- IJHUZMGJRGNXIW-CIUDSAMLSA-N Asp-Glu-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IJHUZMGJRGNXIW-CIUDSAMLSA-N 0.000 description 2
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 2
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 2
- SARSTIZOZFBDOM-FXQIFTODSA-N Asp-Met-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SARSTIZOZFBDOM-FXQIFTODSA-N 0.000 description 2
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 2
- AWPWHMVCSISSQK-QWRGUYRKSA-N Asp-Tyr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O AWPWHMVCSISSQK-QWRGUYRKSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- LLRJEFPKIIBGJP-DCAQKATOSA-N Gln-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N LLRJEFPKIIBGJP-DCAQKATOSA-N 0.000 description 2
- MAGNEQBFSBREJL-DCAQKATOSA-N Gln-Glu-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N MAGNEQBFSBREJL-DCAQKATOSA-N 0.000 description 2
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 2
- FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 2
- QMVCEWKHIUHTSD-GUBZILKMSA-N Gln-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QMVCEWKHIUHTSD-GUBZILKMSA-N 0.000 description 2
- HLRLXVPRJJITSK-IFFSRLJSSA-N Gln-Thr-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HLRLXVPRJJITSK-IFFSRLJSSA-N 0.000 description 2
- ZZLDMBMFKZFQMU-NRPADANISA-N Gln-Val-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O ZZLDMBMFKZFQMU-NRPADANISA-N 0.000 description 2
- LXAUHIRMWXQRKI-XHNCKOQMSA-N Glu-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O LXAUHIRMWXQRKI-XHNCKOQMSA-N 0.000 description 2
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 2
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- WDXLKVQATNEAJQ-BQBZGAKWSA-N Gly-Pro-Asp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WDXLKVQATNEAJQ-BQBZGAKWSA-N 0.000 description 2
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 2
- VSLXGYMEHVAJBH-DLOVCJGASA-N His-Ala-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O VSLXGYMEHVAJBH-DLOVCJGASA-N 0.000 description 2
- QLBXWYXMLHAREM-PYJNHQTQSA-N His-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N QLBXWYXMLHAREM-PYJNHQTQSA-N 0.000 description 2
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 2
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 2
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 2
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 2
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 2
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 2
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 2
- ZAWOJFFMBANLGE-CIUDSAMLSA-N Lys-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N ZAWOJFFMBANLGE-CIUDSAMLSA-N 0.000 description 2
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 2
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 2
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 2
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 2
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 2
- WINFHLHJTRGLCV-BZSNNMDCSA-N Lys-Tyr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 WINFHLHJTRGLCV-BZSNNMDCSA-N 0.000 description 2
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 description 2
- XPVCDCMPKCERFT-GUBZILKMSA-N Met-Ser-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XPVCDCMPKCERFT-GUBZILKMSA-N 0.000 description 2
- 108010066427 N-valyltryptophan Proteins 0.000 description 2
- MFQXSDWKUXTOPZ-DZKIICNBSA-N Phe-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N MFQXSDWKUXTOPZ-DZKIICNBSA-N 0.000 description 2
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 2
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 2
- SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 2
- BJCXXMGGPHRSHV-GUBZILKMSA-N Pro-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BJCXXMGGPHRSHV-GUBZILKMSA-N 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 2
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 2
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 2
- APIQKJYZDWVOCE-VEVYYDQMSA-N Thr-Asp-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O APIQKJYZDWVOCE-VEVYYDQMSA-N 0.000 description 2
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 2
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 2
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 2
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 2
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 2
- LDMUNXDDIDAPJH-VMBFOHBNSA-N Trp-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N LDMUNXDDIDAPJH-VMBFOHBNSA-N 0.000 description 2
- RRVUOLRWIZXBRQ-IHPCNDPISA-N Trp-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RRVUOLRWIZXBRQ-IHPCNDPISA-N 0.000 description 2
- JDWUNEPOEZAZGD-BVSLBCMMSA-N Trp-Phe-Met Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1 JDWUNEPOEZAZGD-BVSLBCMMSA-N 0.000 description 2
- AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 2
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 2
- SDUBQHUJJWQTEU-XUXIUFHCSA-N Val-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C(C)C)N SDUBQHUJJWQTEU-XUXIUFHCSA-N 0.000 description 2
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 2
- MHHAWNPHDLCPLF-ULQDDVLXSA-N Val-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=CC=C1 MHHAWNPHDLCPLF-ULQDDVLXSA-N 0.000 description 2
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 2
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102000006783 calponin Human genes 0.000 description 2
- 108010086826 calponin Proteins 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000010813 internal standard method Methods 0.000 description 2
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 108010068488 methionylphenylalanine Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 108700004896 tripeptide FEG Proteins 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 1
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical class OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 1
- 101710093560 34 kDa protein Proteins 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- YSMYFQQNOQYRTR-UHFFFAOYSA-N ACE inhibitor peptide C 105 Natural products CC(C)CC(NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)O YSMYFQQNOQYRTR-UHFFFAOYSA-N 0.000 description 1
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- PBAMJJXWDQXOJA-FXQIFTODSA-N Ala-Asp-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PBAMJJXWDQXOJA-FXQIFTODSA-N 0.000 description 1
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 1
- GKAZXNDATBWNBI-DCAQKATOSA-N Ala-Met-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N GKAZXNDATBWNBI-DCAQKATOSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 1
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- DXZNJWFECGJCQR-FXQIFTODSA-N Asn-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N DXZNJWFECGJCQR-FXQIFTODSA-N 0.000 description 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 1
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 1
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- GDNWBSFSHJVXKL-GUBZILKMSA-N Cys-Lys-Gln Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O GDNWBSFSHJVXKL-GUBZILKMSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 241001673391 Entandrophragma candollei Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- REJJNXODKSHOKA-ACZMJKKPSA-N Gln-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N REJJNXODKSHOKA-ACZMJKKPSA-N 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- HWEINOMSWQSJDC-SRVKXCTJSA-N Gln-Leu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HWEINOMSWQSJDC-SRVKXCTJSA-N 0.000 description 1
- OACPJRQRAHMQEQ-NHCYSSNCSA-N Gln-Val-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OACPJRQRAHMQEQ-NHCYSSNCSA-N 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 1
- WOSRKEJQESVHGA-CIUDSAMLSA-N Glu-Arg-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O WOSRKEJQESVHGA-CIUDSAMLSA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 1
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 description 1
- XHWLNISLUFEWNS-CIUDSAMLSA-N Glu-Gln-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XHWLNISLUFEWNS-CIUDSAMLSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- XNOWYPDMSLSRKP-GUBZILKMSA-N Glu-Met-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(O)=O XNOWYPDMSLSRKP-GUBZILKMSA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- UWQDKRIZSROAKS-FJXKBIBVSA-N Gly-Met-Thr Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWQDKRIZSROAKS-FJXKBIBVSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000947699 Homo sapiens Microfibril-associated glycoprotein 4 Proteins 0.000 description 1
- HOLOYAZCIHDQNS-YVNDNENWSA-N Ile-Gln-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HOLOYAZCIHDQNS-YVNDNENWSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- IALVDKNUFSTICJ-GMOBBJLQSA-N Ile-Met-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IALVDKNUFSTICJ-GMOBBJLQSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- WOEDRPCHKPSFDT-MXAVVETBSA-N Lys-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCCCN)N WOEDRPCHKPSFDT-MXAVVETBSA-N 0.000 description 1
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 1
- ZCWWVXAXWUAEPZ-SRVKXCTJSA-N Lys-Met-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZCWWVXAXWUAEPZ-SRVKXCTJSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 1
- UROWNMBTQGGTHB-DCAQKATOSA-N Met-Leu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UROWNMBTQGGTHB-DCAQKATOSA-N 0.000 description 1
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
- 101100425896 Mus musculus Tpm1 gene Proteins 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- HPXVFFIIGOAQRV-DCAQKATOSA-N Pro-Arg-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O HPXVFFIIGOAQRV-DCAQKATOSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102100030484 Prostaglandin E synthase 2 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100030262 Regucalcin Human genes 0.000 description 1
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
- CRZRTKAVUUGKEQ-ACZMJKKPSA-N Ser-Gln-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CRZRTKAVUUGKEQ-ACZMJKKPSA-N 0.000 description 1
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- FOOZNBRFRWGBNU-DCAQKATOSA-N Ser-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N FOOZNBRFRWGBNU-DCAQKATOSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 1
- YJVJPJPHHFOVMG-VEVYYDQMSA-N Thr-Met-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YJVJPJPHHFOVMG-VEVYYDQMSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 101710186379 Tropomyosin-1 Proteins 0.000 description 1
- PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- REJBPZVUHYNMEN-LSJOCFKGSA-N Val-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N REJBPZVUHYNMEN-LSJOCFKGSA-N 0.000 description 1
- XTAUQCGQFJQGEJ-NHCYSSNCSA-N Val-Gln-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XTAUQCGQFJQGEJ-NHCYSSNCSA-N 0.000 description 1
- LMSBRIVOCYOKMU-NRPADANISA-N Val-Gln-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N LMSBRIVOCYOKMU-NRPADANISA-N 0.000 description 1
- FTKXYXACXYOHND-XUXIUFHCSA-N Val-Ile-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O FTKXYXACXYOHND-XUXIUFHCSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- VLMZMRDOMOGGFA-WDBKCZKBSA-N festuclavine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C)=C3C2=CNC3=C1 VLMZMRDOMOGGFA-WDBKCZKBSA-N 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 102000044791 human MFAP4 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及对来自人的生物样品进行诊断研究的方法,用于诊断研究肝脏炎症,尤其是肝脏纤维化和/或肝硬变,其中所述样品被研究作为肝脏炎症—尤其是肝脏纤维化和/或肝硬变的标志物的一种或多种蛋白质,其中相对于健康状况,所述蛋白质浓度升高或者降低表明存在肝脏炎症,尤其是肝脏纤维化和/或肝硬化。所述蛋白质选自:ER6Q、波形蛋白、肌动蛋白α1骨骼肌蛋白、hMFAP 4、原肌球蛋白、PTGES 2、淀粉样P-组分、transgelin、钙调理蛋白1、人p20蛋白、17kDa肌球蛋白轻链、H链H Igg B12、脯氨酰4-羟化酶、β亚基亚甲基四氢叶酸脱氢酶1、PRO2619、醛脱氢酶1、纤维蛋白原α链前蛋白原、果糖-二磷酸-醛缩酶B、精氨酸琥珀酸合成酶、Eefla2、ATP 5 A1、α-2-肌动蛋白、调钙素、血清白蛋白、线粒体苹果酸脱氢酶、线粒体乙酰乙酰辅酶A硫解酶、或者在每一情况下,是其部分序列。
Description
本发明涉及一种用于人类肝脏炎症的生物样品的诊断研究的方法,尤其是肝脏纤维化和/或肝硬变,样品被研究因为一种或多种蛋白质作为肝脏炎症的标记物,尤其是肝脏纤维化和/或肝硬变,蛋白质的浓度相对于健康状况提高或降低,这表明肝脏存在炎症,尤其是肝脏纤维化和/或肝硬变中。
全世界大约有1.7亿人慢性感染了丙型肝炎病毒(hepatitis Cvirus(HCV))。病人之间疾病的病程显著不同;虽然大约20%的病人在20年内发展为肝硬化,而在其它病人中,在更长的时间期间后,仍然没有观察到这一类型的发展。除了其它因素之外,可确定会增加肝脏纤维化和/或肝硬变概率的一批因素有,雄性、酒精滥用、HIV或曼氏血吸虫(Schistosoma mansoni)的共感染、遗传易感性和感染时年龄较大。
最重要的是,肝星状细胞(hepatic stellate cells(HSC)),其在休息状态下在正常肝脏中负责维生素A的储存,尤其是,负责肝脏纤维化和/或肝硬变的发展。相反,在纤维化肝脏中,它们被激活,增生,且发展为肌纤维母细胞。这些肌成纤维细胞产生大量胶原蛋白,下调基质金属蛋白酶(matrix metalloproteinases(MMP))的产生,且显示出MMP的生理抑制剂(physiological inhibitors of the MMP(TIMP))的增加性表达。随着增加胶原蛋白积聚,肝脏的纤维化进一步发展,这最后可能导致器官功能衰竭。
尤其是,聚乙二醇化干扰素α(peg-interferon alpha)和利巴韦林(ribavirin(三氮唑核苷))被用于慢性肝炎C的抗病毒治疗。尽管这种方式可以成功地治疗许多病人,但该治疗在至少50%病人中是不成功的,这些病人感染了HCV基因型1,这种HCV基因型1在西方国家是最普遍的。这对感染了HCV基因型4的病人是类似真实的,这种HCV基因型4在埃及频繁发生。此外,持久的抗病毒治疗的成本很高,并且这种治疗与显著的副作用有关。在显著晚期的病人中,抗病毒治疗不再产生期望的成功。因此,存在对能更好地诊断肝炎病人的纤维化以及因此而言肝硬化发生的需求,以及能够为治疗医师提供就抗病毒治疗是否可取以及是否有希望做出决断的能力的需求。
过去许多非侵入性标记物已经被用于肝脏纤维化的检测,在这些非侵入性标记物中,有所谓的acti-test或fibro-test、III型前胶原肽(PIIIP)、透明质酸、基质金属蛋白酶(MMP)以及它们的抑制剂(TIMP)(T.Poynard等人,Expert Rev Mol Diagn.2005,5(1):15-21;V.Leroy等人,J Hep 2001,35(1):26)。然而,所有这些标记物仅仅表现出有限的敏感性和特异性,由于这个原因,存在对更合适的标记物的进一步需求。
从所描述的现有技术出发,因此它自身提出此种目标,即提供研究肝脏炎症和/或肝脏纤维化和/或肝硬变的生物样品的改进方法,其中使用新颖的标记物。
根据本发明,实现了这样的目标,即通过研究人类生物样品的肝脏炎症,尤其是肝脏纤维化和/或肝硬变的方法,样品被研究,目标是一种或多种蛋白质作为肝脏炎症的标记物,尤其是肝脏纤维化和/或肝硬变,以及升高水平的所述蛋白质表明存在肝脏炎症,尤其是肝脏纤维化和/或肝硬变,所述蛋白质选自:ER60、波形蛋白、肌动蛋白α1骨骼肌蛋白、hMFAP4、原肌球蛋白、PTGES2、淀粉样-P-组分、transgelin、钙调节蛋白1、人(Homo sapiens)p20蛋白、17kDa肌球蛋白轻链、H链H IgG B12、脯氨酰4-羟化酶、β亚基。
进一步,本发明也涉及一种相应的方法,其中,降低水平的所述蛋白质表明存在肝脏炎症,尤其是肝脏纤维化和/或肝硬变,在这种情况下,所述蛋白质选自:亚甲基四氢叶酸脱氢酶1、PRO2619、醛脱氢酶1、纤维蛋白原α-链前蛋白原、果糖-二磷酸-醛缩酶B、精氨酸琥珀酸合成酶、Eef1a2、ATP5A1、α-2-肌动蛋白、调钙素、血清白蛋白、线粒体苹果酸脱氢酶、线粒体乙酰乙酰辅酶A硫解酶。
对于上调以及下调蛋白,也根据本发明,通过确定生物标记物(也就是:标志物蛋白)的部分序列,进行了研究。尤其是,这样的部分序列优选包括根据本发明的生物标志物的60%的氨基酸序列,尤其是70%和更多,80%和更多,尤其是90至95%。
在本发明的上下文中,术语肝脏炎症包括任何形式的肝炎,但尤其是肝脏纤维化,直到肝硬变(关于这些术语,例如,请参考相关的Pschyrembel,Klinisches[Clinical Dictionary],260th edition,2004,Berlin)。根据本发明,肝脏纤维化和肝硬变是优选的。
进一步,本发明也涉及肝脏炎症的诊断,尤其是肝脏纤维化和/或肝硬变,针对待研究的病人实施测定选自如下的至少一种蛋白的确定:ER60、波形蛋白、肌动蛋白α1骨骼肌蛋白、hMFAP4、原肌球蛋白、PTGES 2、淀粉样-P-组分、transgelin、钙调节蛋白1、人p20蛋白、17kDa肌球蛋白轻链、H链H IgG B12、脯氨酰4-羟化酶、β亚基、亚甲基四氢叶酸脱氢酶1、PRO2619、醛脱氢酶1、纤维蛋白原α-链前蛋白原、果糖二磷酸醛缩酶B、精氨酸琥珀酸合成酶、Eef1a2、ATP5A1、α-2-肌动蛋白、调钙素、血清白蛋白、线粒体苹果酸脱氢酶、线粒体乙酰乙酰辅酶A硫解酶或其各自的部分序列。
进一步,根据本发明的这些生物标志物和/或标志物蛋白对于根据本发明的诊断是可能的。
与非纤维化组织相比,在纤维化组织的蛋白质组学分析过程中,所引述的蛋白可被鉴定为潜在的生物标志物。为了该目的,从感染了丙型肝炎的病人拿出肝脏活组织检查样品。在手工均质器中用裂解缓冲液均质化样品,DNA和其它细胞材料被除去,得到蛋白质浓缩物。使用染料标记这些蛋白质;使用等电聚焦,使蛋白质在第一个维度经受2-D聚丙烯酰胺凝胶电泳,在第二个维度经受SDS凝胶电泳。借助适合该目的的软件,比较纤维化和非纤维化细胞的结果,检测且量化在纤维化样品中扩大或降低的斑,这是与非纤维化样品相比而言。例如,来自GE Healthcare的ImageQuantTM软件以及该公司的DeCyder软件可作为执行软件。测量且分析用来标记蛋白质的染料的散发。
借助LC-ESI-MS(液相色谱-电喷雾-质谱)完成进一步的分析。首先,借助凝胶中的胰蛋白酶,将蛋白质分解为单一肽片段;其中,在凝胶中,样品在之前已经被分离。借助反相HPLC,将这些片段彼此分离,并且使用质谱法研究这些片段,以鉴定单一蛋白。当然,其它合适的质谱法也可用于该目的,如基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)。
下述蛋白质能在研究中被鉴定,相对于非纤维化细胞,这些蛋白在纤维化细胞中被上调(倍数变化正值)或下调(倍数变化负值):
上调蛋白:
NCBI登记号 | 鉴定蛋白 | 倍数变化 |
IPI00025252.1 | ER60蛋白 | 26.9 |
IPI00418471.5 | 波形蛋白 | 5.6 |
IPI00448938.1 | H链H IgG B12 | 14.7 |
IPI00697648.1 | 肌动蛋白α1骨骼肌蛋白 | 6.5 |
IPI00022792.3 | hMFAP 4 | 45.1 |
IPI00455050.1 | 肌节原肌球蛋白κ | 87.1 |
IPI00014581.1 | TPM1人原肌球蛋白α链 | 28.7 |
IPI00220709.3 | β原肌球蛋白 | 52.4 |
IPI00010779.3 | 原肌球蛋白4 | 20.6 |
IPI00303568.3 | PTGES 2 | 6.1 |
IPI00010796.1 | 脯氨酰4-羟化酶,β亚基 | 4.6 |
IPI00022391.1 | 淀粉样P-组分,血清 | 7.3 |
IPI00216138.5 | transgelin | 15 |
IPI00021264.1 | 钙调节蛋白1 | 21.1 |
IPI00022433.5 | Homo sapiens p20蛋白[pirB53814] | 16.9 |
IPI00718271.2 | 17kDa肌球蛋白轻链 | 8.4 |
下调蛋白:
NCBI登记号 | 简单蛋白 | 倍数变化 |
IPI00218342.9 | 亚甲基四氢叶酸脱氢酶1 | -9.37 |
IPI00745872.1 | PRO2619 | -3.2 |
IPI00218914.4 | 醛脱氢酶1 | -7.7 |
IPI00029717.1 | 纤维蛋白原α-链前蛋白 | -6.4 |
IPI00218407.5 | 果糖二磷酸醛缩酶B | -16.6 |
IPI00020632.4 | 精氨酸琥珀酸合成酶 | -11.0 |
IPI00014424.1 | Eef1a2 | -6.4 |
IPI00440493.2 | ATP5A1 | -5.8 |
IPI00708487.1 | α-2-肌动蛋白;α心脏肌动蛋白 | -8.6 |
IPI00017551.1 | 调钙素(衰老标志蛋白30) | -13.3 |
IPI00708398.1 | ABBOS-血清白蛋白前体 | -13.3 |
IPI00291006.1 | 线粒体苹果酸脱氢酶前体 | -5.9 |
IPI00030363.1 | 线粒体乙酰乙酰辅酶A硫解酶前体 | -5.9 |
NCBI:国家生物技术信息中心
下面详细说明了几个鉴定蛋白的序列信息。肽序列,一方面,导致蛋白质的鉴定,另一方面,允许蛋白质异形体的区别(也对比于本申请所附的序列列表),有黑色加深。
原肌球蛋白
SEQ ID NO 1 MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEEDIAAKEKLL
SEQ ID NO 2 MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEEDIAAKEKLL
SEQ ID NO 3 MDAIKKKMQMLKLDKENAIDRAEQAEADKKQAEDRCKQLEEEQQALQKKL
SEQ ID NO 4 MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEDRSKQLEDELVSLQKKL
SEQ ID NO 5 ------------------------------------MAGLNSLEAVKRKI
SEQ ID NO 1 RVSEDERDRVLEELHKAEDSLLAAEEAAAKAEADVASLNRRIQLVEEELD
SEQ ID NO 2 RVSEDERDRVLEELHKAEDSLLAAEEAAAKAEADVASLNRRIQLVEEELD
SEQ ID NO 3 KGTEDEVEKYSESVKEAQEKLEQAEKKATDAEADVASLNRRIQLVEEELD
SEQ ID NO 4 KGTEDELDKYSEALKDAQEKLELAEKKATDAEADVASLNRRIQLVEEELD
SEQ ID NO 5 QALQQQADEAEDRAQGLQRELDGERERREKAEGDVAALNRRIQLFEEELD
SEQ ID NO 1 RAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKE
SEQ ID NO 2 RAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKE
SEQ ID NO 3 RAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMELQEMQLKE
SEQ ID NO 4 RAQERLATALQKLEEAEKAADESERGMKVIESRAQKDEEKMEIQEIQLKE
SEQ ID NO 5 RAQERLATALQKLEEAEKAADESERGMKVIENRAMKDEEKMEIQEMQLKE
SEQ ID NO 1 AKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGKCAELEEELKTV
SEQ ID NO 2 AKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGKCAELEEELKTV
SEQ ID NO 3 AKHIAEDSDRKYEEVARKLVILEGELERSEERAEVAESRARQLEEELRTM
SEQ ID NO 4 AKHIAEDADRKYEEVARKLVIIESDLERAEERAELSEGQVRQLEEQLRIM
SEQ ID NO 5 AKHIAEEADRKYEEVARKLVILEGELERAEERAEVSELKCGDLEEELKNV
SEQ ID NO 1 TNDLKSLEAQAEKYSQKEDRYEEEIKVLSDKLKEAETRAEFAERSVTKLE
SEQ ID NO 2 TNDLKSLEAQAEKYSQKEDRYEEEIKVLSDKLKEAETRAEFAERSVTKLE
SEQ ID NO 3 DQALKSLMASEEEYSTKEDKYEEEIKLLEEKLKEAETRAEFAERSVAKLE
SEQ ID NO 4 DQTLKALMAAEDKYSQKEDRYEEEIKVLSDKLKEAETRAEFAERSVTKLE
SEQ ID NO 5 TNNLKSLEAASEKYSEKEDKYEEEIKLLSDKLKEAETRAEFAERTVAKLE
SEQ ID NO 1 KSIDDLEDELYAQKLKYKAISEELDHALNDMTSI
SEQ ID NO 2 KSIDDLEDELYAQKLKYKAISEELDHALNDMTSI
SEQ ID NO 3 KTIDDLEETLASAKEENVEIHQTLDQTLLELNNL
SEQ ID NO 4 KSIDDLEEKVAHAKEENLSMHQMLDQTLLELNNM
SEQ ID NO 5 KTIDDLEEKLAQAKEENVGLHQTLDQTLNELNCI
Transgelin
SEQ ID NO 6 MANKGPSYGMSREVQSKIEKKYDEELEERLVEWIIVQCGPDVGRPDRGRL
SEQ ID NO 7 MANKGPSYGMSREVQSKIEKKYDEELEERLVEWIIVQRGPDVGRPDRGRL
SEQ ID NO 6 GFQVWLKNGVILSKLVNSLYPDGSKPVKVPENPPSMVFKQMEQVAQFLKA
SEQ ID NO 7 GFQVWLKNGVILSKLVNSLYPDGSKPVKVPENPPSMVFKQMEQVAQFLKA
SEQ ID NO 6 AEDYGVIKTDMFQTVDLFEGKDMAAVQRTLMALGSLAVTKNDGHYRGDPN
SEQ ID NO 7 AEDYGVIKTDMFQTVDLFEGKDMAAVQRTLMALGSLAVTKNDGHYRGDPN
SEQ ID NO 6 WFMKKAQEHKREFTESQLQEGKHVIGLQMGSNRGASQAGMTGYGRPRQII
SEQ ID NO 7 WFMKKAQEHKREFTESQLQEGKHVIGLQMGSNRG----------------
SEQ ID NO 6 S
SEQ ID NO 7 -
SEQ ID NO 1:肌节原肌球蛋白κ,TPM1-κ;NCBI登记号:IPI00455050.1
SEQ ID NO 2:肌节原肌球蛋白κ;NCBI登记号:IPI00455050.1
SEQ ID NO 3:β原肌球蛋白;NCBI登记号:IPI00220709.3
SEQ ID NO 4:TPM 1人原肌球蛋白1α-链;NCBI登记号:IPI00014581.1
SEQ ID NO 5:原肌球蛋白4;NCBI登记号:IPI00010779.3
SEQ ID NO 6:transgelin;NCBI登记号:IPI00216138.5
SEQ ID NO 7:transgelin变体;NCBI登记号:IPI00216138.5
图1所示为使用2-D凝胶电泳分离的蛋白质的图片,使用了来自总共7个病人的肝脏硬化肝实质的纤维化和非纤维化细胞,这些病人遭遇了丙型肝炎相关的肝硬化。圆形标记表示原肌球蛋白(β),椭圆形标记表示hMFAP4。图片的类似性支持了结果的再现性。
尤其是,原肌球蛋白、transgelin、钙调理蛋白(calponin)、hMFAP4和波形蛋白已经显示出是根据本发明的有希望的且优选的生物标志物。进一步,原肌球蛋白可以是肌节原肌球蛋白κ、β原肌球蛋白、TPM1人原肌球蛋白或原肌球蛋白4。
所引述的hMFAP4是人微纤丝结合蛋白4(the humanmicrofibrillar associated protein 4)。然而,除了上面提及的上调蛋白,下调代谢酶也可被用作标志物,尤其是精氨酰琥珀酸合成酶、亚甲基四氢叶酸脱氢酶、果糖-1,6-二磷酸醛缩酶、线粒体苹果酸脱氢酶和线粒体乙酰乙酰辅酶A硫解酶。
下面简单讨论了一些已鉴别蛋白,这些提供于此,仅仅在于尽力澄清,这些解释不应该理解为以任何方式对寻找专利权的客体的限制。
调钙素,也已知为衰老标志蛋白-30(sensescence markerprotein-30(SMP-30)),通过浆细胞膜、微粒体和线粒体中Ca2+酶的激活,在维持胞内Ca2+水平中起着显著的作用。与健康肝细胞相比,调钙素在纤维化肝细胞中被下调13倍。这可能表明,就患病的肝脏组织中的氧化应激而言,调钙素的补偿效应受到降低。
线粒体苹果酸脱氢酶和线粒体乙酰乙酰基转移酶,两者在纤维化肝组织都被下调5.9倍。这可能说明,丙型肝炎病毒核心蛋白和蛋白NS3和NS5与线粒体之间的相互作用导致形成活性氧(reactiveoxygen species(ROS)),这可能是对纤维化细胞中所引述酶的较弱表达的解释。
纤维化肝脏细胞中受扰线粒体酶的进一步迹象是ATP合成酶α亚基(the ATP synthase alpha-subunit(ATP5A1))的降低表达,它在氧化磷酸化作用中催化ATP合成。
丙型肝炎病毒核心蛋白和NS5A蛋白的进一步作用,是通过与载脂蛋白A1(apolipoprotein A1(apoA1))或A2(apoA2)的交互作用,与内质网的膜、高尔基体和胞内脂质蓄积的扩大有关。脂质转移蛋白受到相当地抑制,或者VLDL(very low density lipoproteins(极低密度脂蛋白))的合成受到干扰。在纤维化肝细胞中,能观察到乙酰基-CoA-乙酰基转移酶的显著下调(倍数变化:-5.88)。
纤维化肝脏的代谢紊乱也表明它们本身在糖酵解酶的降低表达上,例如果糖-1,6-二磷酸醛缩酶(倍数变化:-16.6)、烯醇酶-1(2-磷酸二甘油酸水解酶)或乙二醛酶。
由于这些代谢功能紊乱状态,纤维化肝细胞中的蛋白合成被部分地显著降低:血清白蛋白(倍数变化:-13.2),其功能相当于脂肪酸、类固醇和甲状腺激素的载体,并且稳定胞外液相体积,它仅仅仍然以降低方式被表达。
纤维化肝细胞中肝脏再生的过程明显被亚甲基四氢叶酸脱氢酶(倍数变化:-9.4)的弱表达削弱,其催化四氢叶酸的C-1衍生物转化中的三个顺序反应。未降低的酶功能对正常细胞功能、生长和去分化是重要的。
总的来说,细胞平衡、糖酵解反应途径、脂质区室化和代谢的紊乱似乎存在于纤维化细胞中,这促进了活性氧(ROS)的产生。这些又依次导致肝细胞和肝星状细胞中的TGF-β1合成,为肝纤维发生的最强大的促进剂。
在扩增的可检测蛋白领域,蛋白质肌动蛋白α(倍数变化:6.5)和肌动蛋白γ(倍数变化:9.1)能被鉴定。这些是肌细胞的细肌丝和非肌细胞的细胞骨架的主要组分。肌动蛋白显然是HSC细胞的产物,在丙型肝炎诱导的纤维化事件中以扩增方式发生。
进一步的鉴定蛋白是波形蛋白(倍数变化:4.6)。这被假定为一种来自间充质的肝星状细胞的产物。
多种原肌球蛋白异构体,这些异构体显然不是由肝细胞产生的,而是由肌成纤维性的肝脏星状细胞产生,尤其具有最高的扩增速率(倍数变化:9.7到83.1)。
34kDa蛋白质钙调理蛋白通常也在平滑肌细胞中被特异地表达,并且结合钙调蛋白、肌动蛋白和原肌球蛋白。考虑到肌成纤维细胞激活的肝星状细胞,根据蛋白质组学分析的结果,钙调理蛋白(calponin)也在纤维化细胞中被上调(倍数变化:18.5)。
Transgelin(倍数变化:15)也被假定是肝星状细胞的产物。Transgelin是22kDa蛋白,该蛋白也被称作SM22-α,且与钙调理蛋白有结构类似性。淀粉样成分P,是一种糖蛋白,其包括一对非共价结合的五聚物,亚单位的尺寸为23至25kDa,在纤维化事件中比健康组织中更强地表达(倍数变化:7.3)。直到此刻,肝纤维增生中的生理学功能仍然是未知的,但过度表达表明了一种反常的细胞过程。
总之可以表明,可用作生物标志物的蛋白质的过度表达或者表达异常减弱,归结于:在纤维化肝细胞中,于细胞凋亡过程中,紊乱的细胞平衡、受损的线粒体和代谢酶、降低的细胞合成、和细胞骨架蛋白的扩大表达。
在用作生物标志物的蛋白质样品的研究中,如上面所描述的,可使用一种过程,其中,借助于2-D凝胶电泳,该过程包括第一维度上的等电聚焦,和第二维度上的凝胶电泳,进行蛋白质的分离,并且通过蛋白质模式与非纤维化对照样品的比较,证明特异蛋白质的过度表达和/或表达不足。凝胶电泳优选是SDS聚丙烯酰胺凝胶电泳。分析凝胶的相应软件是可获得的,例如,从GE Healthcare,以DeCyder软件的形式获得。
为了检测蛋白质,在完成2-D凝胶电泳之前,使用染料,优选标记这些样品。染料优选是荧光染料。尤其优选使用Cy2、Cy3和/或Cy5。这些染料是可得到的,例如,从GE Healthcare,Freiburg,Germany。这些是羧甲基靛青染料,两个吲哚分子通过有共轭双键的碳链结合在一起。可促使相应的官能化染料与半胱氨酸侧链的硫醇基团反应,以便将蛋白质共价连接在染料上。为了二硫桥还原的目的,首先借助合适的还原剂还原样品,例如,借助三(2-羧乙基)膦盐酸盐(tris(2-carboxyethyl)phosphine hydrochloride(TCEP))。随后,进行与相应的官能化染料的反应,直到最后通过添加DTT终止反应。然而,其它氨基酸残基借助染料的官能化也是可能的,例如,赖氨酸的侧链。
使用Cy3、Cy5染料系统尤其有利,这在于,除了实际样品,在2-D凝胶电泳过程中也可使用内标法,实际样品和内标法用不同染料(分别用Cy3和Cy5)提供。
当然,除了所引述的染料,也可使用其它(荧光)染料,它们在现有领域是已知的,如荧光素或四甲基罗丹明。
用作标志物的蛋白质的测定和量化,也借助进一步的蛋白质诊断方法进行,这些方法对本技术领域的普通技术人员是已知的,尤其是,使用放射性或荧光标记抗体。尤其是,此处引述了适合该目的的生物分析方法,如免疫组织化学技术、抗体阵列、luminex、ELISA、免疫荧光和放射免疫分析法。也使用适合该目的的进一步生物分析方法进行用作标志物的蛋白质的测定和量化,如质谱法,例如,MRM(多反应监测)或AQUA(绝对量化),借助这些方法,标志物蛋白可被定量地测量。
用于测定蛋白质的样品可以是肝组织样品,这些样品是借助活组织检查拿出的。然而,也可使用(全)血、血清、或者血浆样品,这些样品明显更易于获得。
除了所描述的方法,本发明也涉及使用所引述的蛋白质作为检测肝炎炎症的生物标志物,尤其是肝纤维化的检测。
所引述的根据本发明的标志物蛋白也可用于进一步的实施方案中,用于鉴别诊断,尤其是鉴别诊断早期识别、肝脏疾病的进程预测、严重程度的判断、伴随治疗的进程判断、病因学和体外诊断学。
在进一步的实施方案中,本发明涉及用于完成根据本发明所述方法的试剂盒或诊断设备,所述试剂盒包含至少一个根据本发明的标志物(也可以是:标志物蛋白),以及检测试剂和进一步的助剂。
下面实施例被用来解释本发明,但没有将本发明限定为这些实施例。
实施例
实施例1样品分析:
从感染了基因型1的丙型肝炎的总共7个病人拿出肝实质,这些病人已经经受了肝移植,拿出的肝实质被立刻冷冻在冰上,且于-86℃储存。在显微镜下,在纤维化组织和健康部分之间分离样品组织。沿着纤维化隔膜拿出纤维化材料。使用苏木素对2-D凝胶电泳的层染色,其储存于-20℃。将来自微分离解剖的分离细胞放置在100μL分解缓冲液(tris HCl 30mM;硫脲2M;尿素7M,CHAPS 4%,pH 8.0)中,随后通过应用超声波破碎(6×10s脉冲)。
通过离心去除DNA和其它细胞残余物(12,000g进行五分钟)。确定裂解物的蛋白质浓度。
为了制备内标,通过在1小时的时间间隔内,在黑暗中,于37℃下,应用2nmol三-(2-羧乙基)-膦盐酸盐(TCEP)还原3μg的组织裂解物。使用无水DMF p.a.(2nmol/μl)稀释Cy染料(GEHealthcare,Freiburg,Germany),将4nmol Cy3混合到借助TCEP所还原的样品中。于37℃培养30分钟后,添加4μL DTT(1.08g/mL)终止反应。
将被研究的蛋白质的半胱氨酸氨基酸(3500纤维化细胞,2500非纤维化细胞),在添加4nmol Cy5之前,也通过用2nmol TCEP于37℃在黑暗中温育1小时,而被还原。在彻底混合后,将样品在黑暗中于37℃反应30分钟。通过添加10μL DTT终止反应。
为了准备等电聚焦,加入10μL两性电解质2-4(GEHealthcare)。在进一步彻底混合后,同时处理Cy3-标记的和Cy5-标记的细胞。
随后,进行2-D凝胶电泳,21.25h电压梯度被用于等电聚焦。125mM tris、40%(w/v)甘油、3%(w/v)SDS、65mM DTT、pH 6.8被用于10分钟,作为平衡缓冲液。随后,在第二个维度进行聚丙烯酰胺凝胶电泳。
借助合适的扫描仪(Typhoon 9400,GE Healthcare),在完成凝胶电泳后记录图像,并且借助ImageQuant软件和DeCyder软件(GEHealthcare)进行分析。用这种方式,能在凝胶(DIA)中进行不同的分析,以检测且量化单一斑点。
借助酶胰蛋白酶,在10mM碳酸氢铵缓冲液(pH 7.8)中,于37℃将蛋白分裂过夜。使用乙腈-甲酸混合物将以该方式产生的片段提取两次,用于进一步分割和质谱研究。这是借助与纳米-ES I-MS(电喷雾质谱质谱法)结合的在线-RP-毛细管HPLC进行的。蛋白斑点的完整检测也借助HPLC-MS来进行,结合且使用了合适的蛋白数据库(NCBI,美国国家生物技术信息中心)。
实施例2:蛋白质原肌球蛋白及其在病人血清中的检测
为了该目的,使用Western斑点分析进行蛋白检测。原肌球蛋白能在不同来源的肝硬化病人的血清中可重复性地被鉴别(图2)。
图2:下述病人血清的原肌球蛋白Western斑点:
1:(病人1)丙型肝炎(HepC)肝硬化CHILD C
2:(病人2)肝硬化CHILD C
3:(病人3)肝硬化CHILD C
4:(病人4)肝硬化CHILD C
5:(病人5)肝硬化CHILD C
6:(病人6)肝硬化CHILD A
7:(病人7)肝硬化CHILD A
8:(病人8)正常对照
9:(病人9)正常对照
10:(病人10)正常对照
11:(病人11)正常对照
12:(病人12)乙基-毒性肝硬化CHILD C
13:(病人13)乙基-毒性肝硬化CHILD C
14:(病人14)HepB纤维化
15:(病人15)HepC纤维化
16:原肌球蛋白0,005μg
这些病人,一方面,是有肝硬化和/或纤维化的感染了丙型肝炎病人,另一方面,是有乙基-毒性肝硬化的病人,和一个有肝纤维化的乙型肝炎病人。有肝硬化的病人被进一步划分为不同的CHILD类别,通过引入不同的血液参数,它们提供了关于肝硬化严重程度的信息。分类是从CHILD A进行的,其第二年的存活率为大约100%;直到CHILD C,其存活率为大约30%。在健康对照组的病人血清中不能检测原肌球蛋白带(图2,带8-11)。有趣的是,在有CHILD C分类的丙型肝炎病人中能检测到原肌球蛋白(图2,带1-5),而在有CHILD A肝硬化的硬变病人中,不能检测到蛋白带(图2,带6-7)。此外,研究了乙基-毒性肝硬化(CHILD C分类),也显示了消弱形式的原肌球蛋白的信号,且具有CHILD C分类(图2,带12-13)。进一步,原肌球蛋白带能在乙型肝炎纤维化病人中被检测到,这在丙型肝炎纤维化病人中是不可能的。
序列表
Ruhr-Bochum
<120>肝脏炎症的生物标志物
<130>RUB/Meyer 32-5WO
<140>10 2006 048 249.2
<141>2006-08-10
<160>7
<170>PatentIn version 3.3
<210>l
<211>284
<212>PRT
<213>人肝细胞
<400>l
Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Leu Asp Lys Glu
1 5 10 15
Asn Ala Leu Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Ala Ala
20 25 30
Glu Asp Arg Ser Lys Gln Leu Glu Glu Asp Ile Ala Ala Lys Glu Lys
35 40 45
Leu Leu Arg Val Ser Glu Asp Glu Arg Asp Arg Val Leu Glu Glu Leu
50 55 60
His Lys Ala Glu Asp Ser Leu Leu Ala Ala Glu Glu Ala Ala Ala Lys
65 70 75 80
Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu
85 90 95
Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys
100 105 11G
Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys
115 120 125
Val Ile Glu Ser Arg Ala Gln Lys Asp Glu Glu Lys Met Glu Ile Gln
130 135 140
Glu Ile Gln Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ala Asp Arg
145 150 155 160
Lys Tyr Glu Glu Val Ala Arg Lys Leu Val Ile Ile Glu Ser Asp Leu
165 170 175
Glu Arg Ala Glu Glu Arg Ala Glu Leu Ser Glu Gly Lys Cys Ala Glu
180 185 190
Leu Glu Glu Glu Leu Lys Thr Val Thr Asn Asp Leu Lys Ser Leu Glu
195 200 205
Ala Gln Ala Glu Lys Tyr Ser Gln Lys Glu Asp Arg Tyr Glu Glu Glu
210 215 220
Ile Lys Val Leu Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu
225 230 235 240
Phe Ala Glu Arg Ser Val Thr Lys Leu Glu Lys Ser Ile Asp Asp Leu
245 250 255
Glu Asp Glu Leu Tyr Ala Gln Lys Leu Lys Tyr Lys Ala Ile Ser Glu
260 265 270
Glu Leu Asp His Ala Leu Asn Asp Met Thr Ser Ile
275 280
<210>2
<211>284
<212>PRT
<213>人肝细胞
<400>2
Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Leu Asp Lys Glu
1 5 10 15
Asn Ala Leu Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Ala Ala
20 25 30
Glu Asp Arg Ser Lys Gln Leu Glu Glu Asp Ile Ala Ala Lys Glu Lys
35 40 45
Leu Leu Arg Val Ser Glu Asp Glu Arg Asp Arg Val Leu Glu Glu Leu
50 55 60
His Lys Ala Glu Asp Ser Leu Leu Ala Ala Glu Glu Ala Ala Ala Lys
65 70 75 80
Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu
85 90 95
Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys
100 105 110
Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys
115 120 125
Val Ile Glu Ser Arg Ala Gln Lys Asp Glu Glu Lys Met Glu Ile Gln
130 135 140
Glu Ile Gln Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ala Asp Arg
145 150 155 160
Lys Tyr Glu Glu Val Ala Arg Lys Leu Val Ile Ile Glu Ser Asp Leu
165 170 175
Glu Arg Ala Glu Glu Arg Ala Glu Leu Ser Glu Gly Lys Cys Ala Glu
180 185 190
Leu Glu Glu Glu Leu Lys Thr Val Thr Asn Asp Leu Lys Ser Leu Glu
195 200 205
Ala Gln Ala Glu Lys Tyr Ser Gln Lys Glu Asp Arg Tyr Glu Glu Glu
210 215 220
Ile Lys Val Leu Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu
225 230 235 240
Phe Ala Glu Arg Ser Val Thr Lys Leu Glu Lys Ser Ile Asp Asp Leu
245 250 255
Glu Asp Glu Leu Tyr Ala Gln Lys Leu Lys Tyr Lys Ala Ile Ser Glu
260 265 270
Glu Leu Asp His Ala Leu Asn Asp Met Thr Ser Ile
275 280
<210>3
<211>284
<212>PRT
<213>人肝细胞
<400>3
Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Leu Asp Lys Glu
1 5 10 15
Asn Ala Ile Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Gln Ala
20 25 30
Glu Asp Arg Cys Lys Gln Leu Glu Glu Glu Gln Gln Ala Leu Gln Lys
35 40 45
Lys Leu Lys Gly Thr Glu Asp Glu Val Glu Lys Tyr Ser Glu Ser Val
50 55 60
Lys Glu Ala Gln Glu Lys Leu Glu Gln Ala Glu Lys Lys Ala Thr Asp
65 70 75 80
Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu
85 90 95
Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys
100 105 110
Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys
115 120 125
Val Ile Glu Asn Arg Ala Met Lys Asp Glu Glu Lys Met Glu Leu Gln
130 135 140
Glu Met Gln Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ser Asp Arg
145 150 155 160
Lys Tyr Glu Glu Val Ala Arg Lys Leu Val Ile Leu Glu Gly Glu Leu
165 170 175
Glu Arg Ser Glu Glu Arg Ala Glu Val Ala Glu Ser Arg Ala Arg Gln
180 185 190
Leu Glu Glu Glu Leu Arg Thr Met Asp Gln Ala Leu Lys Ser Leu Met
195 200 205
Ala Ser Glu Glu Glu Tyr Ser Thr Lys Glu Asp Lys Tyr Glu Glu Glu
210 215 220
Ile Lys Leu Leu Glu Glu Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu
225 230 235 240
Phe Ala Glu Arg Ser Val Ala Lys Leu Glu Lys Thr Ile Asp Asp Leu
245 250 255
Glu Glu Thr Leu Ala Ser Ala Lys Glu Glu Asn ValGlu Ile Hi s Gln
260 265 270
Thr Leu Asp Gln Thr Leu Leu Glu Leu Asn Asn Leu
275 280
<210>4
<211>284
<212>PRT
<213>人肝细胞
<400>4
Met Asp Ala Ile Lys Lys Lys Met Gln Met Leu Lys Leu Asp Lys Glu
1 5 10 15
Asn Ala Leu Asp Arg Ala Glu Gln Ala Glu Ala Asp Lys Lys Ala Ala
20 25 30
Glu Asp Arg Ser Lys Gln Leu Glu Asp Glu Leu Val Ser Leu Gln Lys
35 40 45
Lys Leu Lys Gly Thr Glu Asp Glu Leu Asp Lys Tyr Ser Glu Ala Leu
50 55 60
Lys Asp Ala Gln Glu Lys Leu Glu Leu Ala Glu Lys Lys Ala Thr Asp
65 70 75 80
Ala Glu Ala Asp Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu
85 90 95
Glu Glu Leu Asp Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys
100 105 110
Leu Glu Glu Ala Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys
115 120 125
Val Ile Glu Ser Arg Ala Gln Lys Asp Glu Glu Lys Met Glu Ile Gln
130 135 140
Glu Ile Gln Leu Lys Glu Ala Lys His Ile Ala Glu Asp Ala Asp Arg
145 150 155 160
Lys Tyr Glu Glu Val Ala Arg Lys Leu Val Ile Ile Glu Ser Asp Leu
165 170 175
Glu Arg Ala Glu Glu Arg Ala Glu Leu Ser Glu Gly Gln Val Arg Gln
180 185 190
Leu Glu Glu Gln Leu Arg Ile Met Asp Gln Thr Leu Lys Ala Leu Met
195 200 205
Ala Ala Glu Asp Lys Tyr Ser Gln Lys Glu Asp Arg Tyr Glu Glu Glu
210 215 220
Ile Lys Val Leu Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu
225 230 235 240
Phe Ala Glu Arg Ser Val Thr Lys Leu Glu Lys Ser Ile Asp Asp Leu
245 250 255
Glu Glu Lys Val Ala His Ala Lys Glu Glu Asn Leu Ser Met His Gln
260 265 270
Met Leu Asp Gln Thr Leu Leu Glu Leu Asn Asn Met
275 280
<210>5
<211>248
<212>PRT
<213>人肝细胞
<400>5
Met Ala Gly Leu Asn Ser Leu Glu Ala Val Lys Arg Lys Ile Gln Ala
1 5 10 15
Leu Gln Gln Gln Ala Asp Glu Ala Glu Asp Arg Ala Gln Gly Leu Gln
20 25 30
Arg Glu Leu Asp Gly Glu Arg Glu Arg Arg Glu Lys Ala Glu Gly Asp
35 40 45
Val Ala Ala Leu Asn Arg Arg Ile Gln Leu Phe Glu Glu Glu Leu Asp
50 55 60
Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys Leu Glu Glu Ala
65 70 75 80
Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys Val Ile Glu Asn
85 90 95
Arg Ala Met Lys Asp Glu Glu Lys Met Glu Ile Gln Glu Met Gln Leu
100 105 110
Lys Glu Ala Lys His Ile Ala Glu Glu Ala Asp Arg Lys Tyr Glu Glu
115 120 125
Val Ala Arg Lys Leu Val Ile Leu Glu Gly Glu Leu Glu Arg Ala Glu
130 135 140
Glu Arg Ala Glu Val Ser Glu Leu Lys Cys Gly Asp Leu Glu Glu Glu
145 150 155 160
Leu Lys Asn Val Thr Asn Asn Leu Lys Ser Leu Glu Ala Ala Ser Glu
165 170 175
Lys Tyr Ser Glu Lys Glu Asp Lys Tyr Glu Glu Glu Ile Lys Leu Leu
180 185 190
Ser Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu Phe Ala Glu Arg
195 200 205
Thr Val Ala Lys Leu Glu Lys Thr Ile Asp Asp Leu Glu Glu Lys Leu
210 215 220
Ala Gln Ala Lys Glu Glu Asn Val Gly Leu His Gln Thr Leu Asp Gln
225 230 235 240
Thr Leu Asn Glu Leu Asn Cys Ile
245
<210>6
<211>201
<212>PRT
<213>人肝细胞
<400>6
Met Ala Asn Lys Gly Pro Ser Tyr Gly Met Ser Arg Glu Val Gln Ser
1 5 10 15
Lys Ile Glu Lys Lys Tyr Asp Glu Glu Leu Glu Glu Arg Leu Val Glu
20 25 30
Trp Ile Ile Val Gln Cys Gly Pro Asp Val Gly Arg Pro Asp Arg Gly
35 40 45
Arg Leu Gly Phe Gln Val Trp Leu Lys Asn Gly Val Ile Leu Ser Lys
50 55 60
Leu Val Asn Ser Leu Tyr Pro Asp Gly Ser Lys Pro Val Lys Val Pro
65 70 75 80
Glu Asn Pro Pro Ser Met Val Phe Lys Gln Met Glu Gln Val Ala Gln
85 90 95
Phe Leu Lys Ala Ala Glu Asp Tyr Gly Val Ile Lys Thr Asp Met Phe
100 105 110
Gln Thr Val Asp Leu Phe Glu Gly Lys Asp Met Ala Ala Val Gln Arg
115 120 125
Thr Leu Met Ala Leu Gly Ser Leu Ala Val Thr Lys Asn Asp Gly His
130 135 140
Tyr Arg Gly Asp Pro Asn Trp Phe Met Lys Lys Ala Gln Glu His Lys
145 150 155 160
Arg Glu Phe Thr Glu Ser Gln Leu Gln Glu Gly Lys His Val Ile Gly
165 170 175
Leu Gln Met Gly Ser Ash Arg Gly Ala Ser Gln Ala Gly Met Thr Gly
180 185 190
Tyr Gly Arg Pro Arg Gln Ile Ile Ser
195 200
<210>7
<211>184
<212>PRT
<213>人肝细胞
<400>7
Met Ala Asn Lys Gly Pro Ser Tyr Gly Met Ser Arg Glu Val Gln Ser
1 5 10 15
Lys Ile Glu Lys Lys Tyr Asp Glu Glu Leu Glu Glu Arg Leu Val Glu
20 25 30
Trp Ile Ile Val Gln Arg Gly Pro Asp Val Gly Arg Pro Asp Arg Gly
35 40 45
Arg Leu Gly Phe Gln Val Trp Leu Lys Asn Gly Val Ile Leu Ser Lys
50 55 60
Leu Val Asn Ser Leu Tyr Pro Asp Gly Ser Lys Pro Val Lys Val Pro
65 70 75 80
Glu Asn Pro Pro Ser Met Val Phe Lys Gln Met Glu Gln Val Ala Gln
85 90 95
Phe Leu Lys Ala Ala Glu Asp Tyr Gly Val Ile Lys Thr Asp Met Phe
100 105 110
Gln Thr Val Asp Leu Phe Glu Gly Lys Asp Met Ala Ala Val Gln Arg
115 120 125
Thr Leu Met Ala Leu Gly Ser Leu Ala Val Thr Lys Asn Asp Gly His
130 135 140
Tyr Arg Gly Asp Pro Asn Trp Phe Met Lys Lys Ala Gln Glu His Lys
145 150 155 160
Arg Glu Phe Thr Glu Ser Gln Leu Gln Glu Gly Lys His Val Ile Gly
165 170 175
Leu Gln Met Gly Ser Asn Arg Gly
180
Claims (14)
1.检测生物样品中ER60的浓度的检测试剂在制备试剂盒或诊断设备中的用途,所述试剂盒或诊断设备用于肝脏纤维化和/或肝硬变的诊断。
2.如权利要求1的用途,其中所述试剂盒或诊断设备还包含检测生物样品中选自如下所述的至少一种蛋白质的浓度的检测试剂:波形蛋白、肌动蛋白α1骨骼肌蛋白、hMFAP4、原肌球蛋白、PTGES2、淀粉样P-组分、transgelin、钙调理蛋白1、人p20蛋白、17kDa肌球蛋白轻链、H链H IgG B12、脯氨酰4-羟化酶β亚基、亚甲基四氢叶酸脱氢酶1、PR02619、醛脱氢酶1、纤维蛋白原α链前蛋白原、果糖-二磷酸-醛缩酶B、精氨酸琥珀酸合成酶、Eef1a2、ATP5A1、α-2-肌动蛋白、调钙素、血清白蛋白、线粒体苹果酸脱氢酶、线粒体乙酰乙酰辅酶A硫解酶。
3.如权利要求2的用途,特征在于:原肌球蛋白是肌节原肌球蛋白κ、β原肌球蛋白、TPM1人原肌球蛋白、或原肌球蛋白4。
4.如权利要求1至3中的任何一项所述的用途,特征在于:所述试剂盒或诊断设备用于生物分析方法。
5.如权利要求4所述的用途,所述生物分析方法为免疫组织化学技术、抗体阵列、luminex、ELISA、免疫荧光或放射免疫分析法。
6.如权利要求1至3中的任何一项所述的用途,特征在于:所述试剂盒或诊断设备用于质谱法以定量确定标志蛋白质。
7.如权利要求6的用途,所述质谱法为多反应监测MRM质谱法或绝对量化AQUA质谱法。
8.如权利要求1至3中的任何一项所述的用途,特征在于:所述试剂盒或诊断设备用于2-D电泳,第一维度为等电聚焦,第二维度为凝胶电泳。
9.如权利要求8的用途,特征在于:凝胶电泳是SDS-聚丙烯酰胺凝胶电泳。
10.如权利要求8的用途,特征在于:所述试剂盒或诊断设备包含在进行2-D电泳之前对样品进行标记的染料。
11.如权利要求10的用途,特征在于:染料是Cy2、Cy3和/或Cy5。
12.如权利要求1至3中的任何一项所述的用途,特征在于:样品是肝脏活组织检查样品。
13.如权利要求1至3中的任何一项所述的用途,特征在于:样品是血清、血浆或全血。
14.根据权利要求1至3任一项的用途,所述试剂盒或诊断设备用于鉴别诊断早期识别、肝脏疾病的进程预测、严重程度的判断、伴随治疗的进程判断、病因学和体外诊断学。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006037613.7 | 2006-08-10 | ||
DE102006037613 | 2006-08-10 | ||
DE102006048249A DE102006048249A1 (de) | 2006-08-10 | 2006-10-12 | Biomarker für Leberentzündung |
DE102006048249.2 | 2006-10-12 | ||
PCT/DE2007/001427 WO2008017303A2 (de) | 2006-08-10 | 2007-08-10 | Biomarker für leberentzündung |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310424171.2A Division CN103630693A (zh) | 2006-08-10 | 2007-08-10 | 肝脏炎症的生物标志物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101611317A CN101611317A (zh) | 2009-12-23 |
CN101611317B true CN101611317B (zh) | 2013-09-18 |
Family
ID=38922186
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310424171.2A Pending CN103630693A (zh) | 2006-08-10 | 2007-08-10 | 肝脏炎症的生物标志物 |
CN200780029721.3A Expired - Fee Related CN101611317B (zh) | 2006-08-10 | 2007-08-10 | 肝脏炎症的生物标志物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310424171.2A Pending CN103630693A (zh) | 2006-08-10 | 2007-08-10 | 肝脏炎症的生物标志物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8535896B2 (zh) |
EP (5) | EP2437064B1 (zh) |
CN (2) | CN103630693A (zh) |
AT (1) | ATE518143T1 (zh) |
AU (1) | AU2007283312B2 (zh) |
CA (1) | CA2660257A1 (zh) |
DE (1) | DE102006048249A1 (zh) |
HK (1) | HK1135184A1 (zh) |
WO (1) | WO2008017303A2 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006048249A1 (de) * | 2006-08-10 | 2008-02-14 | Wolff Prof. Dr. Schmiegel | Biomarker für Leberentzündung |
EP2302359A1 (en) | 2009-09-24 | 2011-03-30 | Université De Reims Champagne-Ardenne | Serum infrared spectroscopy for non invasive assessment of hepatic fibrosis in patients with chronic liver disease |
EP2405271A1 (en) * | 2010-07-06 | 2012-01-11 | Bio-Rad Innovations | Markers of vulnerability of the atherosclerosis plaque |
CN102507936B (zh) * | 2011-11-09 | 2013-10-23 | 北京正旦国际科技有限责任公司 | 一种肝癌标志物多抗免疫质谱试剂盒 |
CN103808944B (zh) * | 2014-03-07 | 2016-04-20 | 高平 | 生物标志物vwf和adamts13及其在肝硬化诊断试剂中的用途 |
CN105785039B (zh) * | 2016-04-01 | 2017-08-04 | 北京理工大学 | 阶梯式定量检测血浆中血清白蛋白及纤维蛋白原的方法 |
CN108990420B (zh) * | 2016-05-29 | 2022-06-24 | 深圳市绘云生物科技有限公司 | 肝病相关生物标志物和其使用方法 |
GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
CN108572251B (zh) * | 2018-05-31 | 2020-01-17 | 中国科学院昆明动物研究所 | 肝硬化早期小分子标志物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022987A2 (en) * | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US7247426B2 (en) * | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
CA2515096A1 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
TWI281473B (en) * | 2003-12-19 | 2007-05-21 | Ind Tech Res Inst | Biomarkers for liver diseases and method for using same |
JP2007315752A (ja) * | 2004-08-16 | 2007-12-06 | Ajinomoto Co Inc | 肝線維化ステージの判定方法 |
TW200745556A (en) * | 2006-01-24 | 2007-12-16 | Ind Tech Res Inst | Biomarkers for liver fibrotic injury |
DE102006048249A1 (de) * | 2006-08-10 | 2008-02-14 | Wolff Prof. Dr. Schmiegel | Biomarker für Leberentzündung |
-
2006
- 2006-10-12 DE DE102006048249A patent/DE102006048249A1/de not_active Withdrawn
-
2007
- 2007-08-10 EP EP11187569.6A patent/EP2437064B1/de not_active Not-in-force
- 2007-08-10 EP EP11187588A patent/EP2437066A3/de not_active Withdrawn
- 2007-08-10 CN CN201310424171.2A patent/CN103630693A/zh active Pending
- 2007-08-10 EP EP11175127A patent/EP2388595A3/de not_active Withdrawn
- 2007-08-10 AU AU2007283312A patent/AU2007283312B2/en not_active Ceased
- 2007-08-10 AT AT07801230T patent/ATE518143T1/de active
- 2007-08-10 US US12/377,058 patent/US8535896B2/en not_active Expired - Fee Related
- 2007-08-10 CA CA002660257A patent/CA2660257A1/en not_active Abandoned
- 2007-08-10 EP EP07801230A patent/EP2052254B1/de not_active Not-in-force
- 2007-08-10 WO PCT/DE2007/001427 patent/WO2008017303A2/de active Application Filing
- 2007-08-10 EP EP11187578A patent/EP2437065A3/de not_active Withdrawn
- 2007-08-10 CN CN200780029721.3A patent/CN101611317B/zh not_active Expired - Fee Related
-
2010
- 2010-02-12 HK HK10101636.6A patent/HK1135184A1/xx not_active IP Right Cessation
-
2013
- 2013-09-10 US US14/022,993 patent/US20140045718A1/en not_active Abandoned
Non-Patent Citations (7)
Title |
---|
Blanc等.Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C.《Proteomics》.2005,第5卷(第14期), * |
Hirano等.Molecular Cloning of the Human Glucose-Regulated Protein ERp57GRP58, a Thiol-Dependent Reductase.《Europe journal of Biochemistry》.1995,第234卷(第1期), * |
Hirano等.MolecularCloningoftheHumanGlucose-RegulatedProteinERp57GRP58 a Thiol-Dependent Reductase.《Europe journal of Biochemistry》.1995 |
Kita等.Evidence for phosphorylation of ratliverglucose-regulatedprotein58, GRP58_ERp57_ER-60, induced by fasting and leptin.《FEBS Letters》.2006,第580卷(第1期), * |
Shackel等.Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization.《HEPATOLOGY,》.2003,第38卷(第3期), * |
Smith等.Hepatitis C virus and liver disease--Global transcriptional profiling and identification of potential markers.《HEPATOLOGY》.2003,第38卷(第6期), * |
Yun等.Nuclear matrix protein expressions in hepatocytes of normal and cirrhotic rat livers under normal and regenerating conditions.《Journal of Cellular Biochemistry》.2004,第91卷(第6期), * |
Also Published As
Publication number | Publication date |
---|---|
EP2437064A3 (de) | 2012-08-29 |
AU2007283312B2 (en) | 2013-09-12 |
WO2008017303A9 (de) | 2009-06-04 |
US20140045718A1 (en) | 2014-02-13 |
ATE518143T1 (de) | 2011-08-15 |
WO2008017303A2 (de) | 2008-02-14 |
EP2052254B1 (de) | 2011-07-27 |
CN103630693A (zh) | 2014-03-12 |
EP2437064A2 (de) | 2012-04-04 |
CN101611317A (zh) | 2009-12-23 |
EP2437065A2 (de) | 2012-04-04 |
WO2008017303A3 (de) | 2008-06-26 |
AU2007283312A1 (en) | 2008-02-14 |
EP2388595A2 (de) | 2011-11-23 |
DE102006048249A1 (de) | 2008-02-14 |
US20100240545A1 (en) | 2010-09-23 |
EP2388595A3 (de) | 2012-08-29 |
EP2437065A3 (de) | 2012-08-29 |
EP2437066A3 (de) | 2012-08-29 |
HK1135184A1 (en) | 2010-05-28 |
EP2437066A2 (de) | 2012-04-04 |
CA2660257A1 (en) | 2008-02-14 |
US8535896B2 (en) | 2013-09-17 |
EP2437064B1 (de) | 2015-02-25 |
EP2052254A2 (de) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101611317B (zh) | 肝脏炎症的生物标志物 | |
Thongboonkerd et al. | Renal and urinary proteomics: current applications and challenges | |
ES2534432T3 (es) | Biomarcadores de riñón sano | |
Sigdel et al. | Shotgun proteomics identifies proteins specific for acute renal transplant rejection | |
Zürbig et al. | The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease | |
EP3260866B1 (en) | Novel biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers | |
Kanda et al. | Detection of titin fragments in urine in response to exercise-induced muscle damage | |
KR20040032826A (ko) | 단백질 프로파일링에 의한 신장 질병 검출 방법 | |
Chiaradia et al. | Gambling on putative biomarkers of osteoarthritis and osteochondrosis by equine synovial fluid proteomics | |
KR20110005708A (ko) | 심장 동종이식 급성 거부반응 진단방법 | |
EP2444814B1 (en) | Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders | |
JP5701994B2 (ja) | シトルリン化タンパク質:生理学的および病理学的疾患のマーカーとしての心筋タンパク質の翻訳後修飾 | |
IL292342A (en) | Biomarkers and their uses for the diagnosis of the silent phase in Alzheimer's disease | |
CN111521828A (zh) | Rsph9作为少弱精症诊断标志物或治疗靶点的应用 | |
Bannaga et al. | Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study | |
Waybright et al. | Characterization of the human ventricular cerebrospinal fluid proteome obtained from hydrocephalic patients | |
Wai-Hoe et al. | Proteomics and detection of uromodulin in first-time renal calculi patients and recurrent renal calculi patients | |
Tammen et al. | Oncopeptidomics–a commentary on opportunities and limitations | |
Gomez et al. | Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis | |
DK2286240T3 (en) | Biomarker of osteoarthritis and use thereof | |
Gillott et al. | Specific isoforms of leucine-rich α2-glycoprotein detected in the proliferative endometrium of women undergoing assisted reproduction are associated with spontaneous pregnancy | |
Rajčević | iTRAQ-Based LC-LC MALDI TOF/TOF MS Quantitative Analysis of Membrane Proteins from Human Glioma | |
Ruiz-Romero et al. | Use of biomarkers for the purposes of diagnosis and drug discovery programs: where do we stand? | |
Marfà Bruix et al. | Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1135184 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1135184 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20140810 |
|
EXPY | Termination of patent right or utility model |